Schering Intron A recall
Executive Summary
Schering-Plough recalls four lots of Intron A (interferon alfa-2b) after stability tests find it to be subpotent 30 days following reconstitution. The lots are manufactured at company's Ireland plant; Schering is sorting out cGMP compliance problems at its Puerto Rico and New Jersey facilities (1"The Pink Sheet" July 2, p. 25). The recalled lots were due to expire between Oct. 20 and Aug. 2, 2002
You may also be interested in...
PEG-Intron Access Program Requires ID Number, Designed To Ensure Supply
Schering-Plough is implementing a prescription tracking program for PEG-Intron to ensure that existing patients will have adequate supply of peginterferon alfa-2b
PEG-Intron Access Program Requires ID Number, Designed To Ensure Supply
Schering-Plough is implementing a prescription tracking program for PEG-Intron to ensure that existing patients will have adequate supply of peginterferon alfa-2b
Orphan Medical Xyrem safety data
Safety data on Orphan Medical's Xyrem (sodium oxybate) in respiratory-compromised patients may be collected post-approval if FDA accepts submission of data on that patient population from an earlier trial, Orphan says. A July 2 "approvable" letter for the narcolepsy treatment indicated that a study would be required before approval. Orphan plans to file the additional data in mid-November and expects a six-month review